Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MNX1 antisense RNA 2 (MNX1-AS2) is a long non-coding antisense RNA located at the *MNX1* gene locus on chromosome 7q36.3[1]. As an antisense transcript, it is distinct from the canonical MNX1 mRNA and is transcribed from a separate intergenic promoter. While much less studied than its paralog MNX1-AS1, MNX1-AS2 participates in the regulation of gene expression through epigenetic and transcriptional mechanisms, impacting biological processes such as cell cycle, chromatin remodeling, differentiation, and development[1]. Recent pan-cancer transcriptomic studies have demonstrated that MNX1-AS2, despite limited functional characterization, shows differential expression across various tumor types (notably gastrointestinal and testicular cancers) and can help distinguish between tumor subtypes and normal tissue with moderate accuracy. Its expression signature, particularly when combined with MNX1 and MNX1-AS1, holds promise as a biomarker for cancer diagnosis and possibly prognosis[1][2]. However, no therapeutic drugs directly target MNX1-AS2, and its precise molecular mechanisms remain largely unexplored.
Not applicable, as there are no drugs that directly target MNX1-AS2 yet.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MNX1 antisense RNA 2 (MNX1-AS2).